KhalKhal Ensieh, Razzaghi Zahra, Zali Hakimeh, Bahadorimonfared Ayad, Iranshahi Majid, Rostami-Nejad Mohammad
Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Gastroenterol Hepatol Bed Bench. 2019;12(Suppl1):S108-S116.
The aim of this study is to explore the expression of genes associated to celiac disease (CD) in the target tissue and peripheral blood monocytes (PBMC) or serum to introduce possible potential biomarkers.
Celiac disease (CD) is an autoimmune disease induced by gluten ingestion in genetically predisposed individuals. Despite technological progress, small intestine biopsy is still the gold standard for diagnosis of CD.
CD data were collected from public databases (proteomics and microarray-based techniques documents). Differentially expressed genes (DEGs) in PBMC or serum as well as small intestinal biopsies from celiac patients compared to normal were collected and analyzed to introduce common individuals. Gene ontology was done to identify the involved biological terms.
Among 598 CD genes in biopsies and 260 genes in PBMC or serum, 32 common genes with a similar expression pattern in both sources were identified. A total of 48 biological terms were introduced which were involved in the CD via the determined DEGs. "Cytokine activity" was the most expanded one of the biological terms.
In this analysis, it was concluded that 32 potential biomarkers of CD can be assessed by complementary research to introduce effective and available biomarkers in biopsy and blood.
本研究旨在探索与乳糜泻（CD）相关的基因在靶组织、外周血单核细胞（PBMC）或血清中的表达情况，以引入可能的潜在生物标志物。
乳糜泻（CD）是一种在具有遗传易感性的个体中由摄入麸质引发的自身免疫性疾病。尽管技术不断进步，但小肠活检仍是诊断CD的金标准。
从公共数据库（基于蛋白质组学和微阵列技术的文献）收集CD数据。收集并分析乳糜泻患者与正常人相比在PBMC或血清以及小肠活检中的差异表达基因（DEG），以找出共同的基因。进行基因本体分析以识别相关的生物学术语。
在活检中的598个CD基因以及PBMC或血清中的260个基因中，鉴定出32个在两种来源中具有相似表达模式的共同基因。通过确定的DEG共引入了48个与CD相关的生物学术语。“细胞因子活性”是生物学术语中扩展最多的一个。
在本分析中，得出的结论是，可以通过补充研究评估32个CD潜在生物标志物，以便在活检和血液中引入有效且可用的生物标志物。
